Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
Standard BioTools (NASDAQ: LAB) has announced its upcoming first quarter 2025 financial results release and conference call schedule.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Standard BioTools (NASDAQ: LAB) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will disclose its Q1 2025 results on Tuesday, May 6, 2025, after the market closes.
A conference call and webcast are scheduled for the same day at 4:30 p.m. ET. Investors can participate through the following dial-in numbers:
- US domestic: (888) 346-3970
- International: (412) 902-4297
The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com for future reference.
Details
News Market Reaction – LAB
The recorded move for LAB in the trading session of this news was +6.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Individuals can access the conference call by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:
David Holmes
ir@standardbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.